指南与共识肝病

AGA临床实践更新:瘦型个体非酒精性脂肪性肝病的诊断与管理专家综述

AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
指南 / 共识 · Gastroenterology · 2022-07-14

美国胃肠病学会(AGA)发布临床实践更新,为瘦型非酒精性脂肪性肝病(NAFLD)患者提供诊断、分期和管理的最佳实践建议。瘦型NAFLD定义为体重指数<25 kg/m2(非亚洲人)或<23 kg/m2(亚洲人),与心血管、肝脏和全因死亡率增加相关。建议包括合并症评估、纤维化风险分层、生活方式干预(减重3%-5%)及特定药物考虑。

要点

  • 瘦型NAFLD诊断标准:BMI<25 kg/m2(非亚洲人)或BMI<23 kg/m2(亚洲人)。
  • 应常规评估合并症(2型糖尿病、血脂异常、高血压)并进行肝纤维化风险分层。
  • 生活方式干预建议减重3%-5%;维生素E或吡格列酮可考虑用于活检证实的NASH。

核心结论

  • 瘦型NAFLD与心血管、肝脏和全因死亡率增加相关,需基于证据进行诊断、分期和管理。

研究设计与样本

  • 美国胃肠病学会(AGA)临床实践更新专家综述,经AGA研究所临床实践更新委员会和AGA理事会批准,并经过内部和外部同行评议。

主要发现

  • NAFLD影响超过25%的美国及全球人群,其中约7%-20%的NAFLD个体为瘦型体质。
  • 瘦型NAFLD患者相对于无NAFLD者,心血管、肝脏和全因死亡率增加。

关键数值与推荐

  • 最佳实践建议1:瘦型NAFLD应在BMI<25 kg/m2(非亚洲人)或BMI<23 kg/m2(亚洲人)的NAFLD个体中诊断。
  • 最佳实践建议2:瘦型NAFLD个体应常规评估合并症,如2型糖尿病、血脂异常和高血压。
  • 最佳实践建议3:瘦型NAFLD个体应进行肝纤维化风险分层,以识别晚期纤维化或肝硬化。
  • 最佳实践建议4:普通人群中的瘦型个体不应常规筛查NAFLD;但年龄>40岁且患有2型糖尿病的个体应考虑筛查。
  • 最佳实践建议5:瘦型个体若患有代谢性疾病(如2型糖尿病、血脂异常、高血压)、肝生化指标升高或偶然发现的肝脂肪变性,应考虑NAFLD。

临床怎么用

  • 最佳实践建议6:临床医生应常规询问所有瘦型NAFLD患者的酒精消费模式。
  • 最佳实践建议7:瘦型NAFLD患者应排除其他肝病原因,包括HIV、脂肪营养不良、溶酶体酸性脂肪酶缺乏症、家族性低β脂蛋白血症和药物性肝脂肪变性(甲氨蝶呤、胺碘酮、他莫昔芬和类固醇)。
  • 最佳实践建议8:当前证据不足以支持对瘦型NAFLD患者进行常规基因变异检测。
  • 最佳实践建议9:若对肝损伤原因和/或肝纤维化分期存在不确定性,应考虑肝活检作为参考标准。
  • 最佳实践建议10:血清指标(NAFLD纤维化评分和Fibrosis-4评分)和影像技术(瞬时弹性成像和磁共振弹性成像)可作为肝活检的替代方法用于纤维化分期和患者随访;这些检测可在诊断时进行,并根据纤维化分期和患者对干预的反应,每隔6个月至2年重复。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: Nonalcoholic fatty liver disease (NAFLD) is well recognized as a leading etiology for chronic liver disease, affecting >25% of the US and global populations. Up to 1 in 4 individuals with NAFLD have nonalcoholic steatohepatitis, which is associated with significant morbidity and mortality due to complications of liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Although NAFLD is observed predominantly in persons with obesity and/or type 2 diabetes mellitus, an estimated 7%-20% of individuals with NAFLD have lean body habitus. Limited guidance is available to clinicians on appropriate clinical evaluation in lean individuals with NAFLD, such as for inherited/genetic disorders, lipodystrophy, drug-induced NAFLD, and inflammatory disorders. Emerging data now provide more robust evidence to define the epidemiology, natural history, prognosis, and mortality of lean individuals with NAFLD. Multiple studies have found that NAFLD among lean individuals is associated with increased cardiovascular, liver, and all-cause mortality relative to those without NAFLD. This American Gastroenterological Association Clinical Practice Update provides Best Practice Advice to assist clinicians in evidence-based approaches to the diagnosis, staging, and management of NAFLD in lean individuals. METHODS: This expert review was commissioned and approved by the American Gastroenterological Association (AGA) Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Gastroenterology. Best Practice Advice Statements BEST PRACTICE ADVICE 1: Lean NAFLD should be diagnosed in individuals with NAFLD and body mass index <25 kg/m2 (non-Asian race) or body mass index <23 kg/m2 (Asian race). BEST PRACTICE ADVICE 2: Lean individuals with NAFLD should be evaluated routinely for comorbid conditions, such as type 2 diabetes mellitus, dyslipidemia, and hypertension. BEST PRACTICE ADVICE 3: Lean individuals with NAFLD should be risk stratified for hepatic fibrosis to identify those with advanced fibrosis or cirrhosis. BEST PRACTICE ADVICE 4: Lean individuals in the general population should not undergo routine screening for NAFLD; however, screening should be considered for individuals older than 40 years with type 2 diabetes mellitus. BEST PRACTICE ADVICE 5: NAFLD should be considered in lean individuals with metabolic diseases (such as type 2 diabetes mellitus, dyslipidemia, and hypertension), elevated liver biochemical tests, or incidentally noted hepatic steatosis. BEST PRACTICE ADVICE 6: Clinicians should query patients routinely regarding alcohol consumption patterns in all patients with lean NAFLD. BEST PRACTICE ADVICE 7: In patients with lean NAFLD, other causes of liver disease should be ruled out, including other causes of fatty liver, such as HIV, lipodystrophy, lysosomal acid lipase deficiency, familial hypobetalipoproteinemia, and medication-induced hepatic steatosis (methotrexate, amiodarone, tamoxifen, and steroids). BEST PRACTICE ADVICE 8: Current evidence is inadequate to support routine testing for genetic variants in patients with lean NAFLD. BEST PRACTICE ADVICE 9: Liver biopsy, as the reference standard, should be considered if there is uncertainty regarding contributing causes of liver injury and/or the stage of liver fibrosis. BEST PRACTICE ADVICE 10: Serum indices (NAFLD fibrosis score and Fibrosis-4 score) and imaging techniques (transient elastography and magnetic resonance elastography) may be used as alternatives to liver biopsy for fibrosis staging and patient follow-up. These tests can be performed at the time of diagnosis and repeated at intervals of 6 months to 2 years, depending on fibrosis stage and the patient's response to intervention. BEST PRACTICE ADVICE 11: If noninvasive tests (eg, Fibrosis-4 and NAFLD fibrosis score) are indeterminate, a second noninvasive test (eg, transient elastography or magnetic resonance elastography) should be performed to confirm the stage and prognosis of NAFLD. BEST PRACTICE ADVICE 12: In lean patients with NAFLD, lifestyle intervention, including exercise, diet modification, and avoidance of fructose- and sugar-sweetened drinks, to target a modest weight loss of 3%-5% is suggested. BEST PRACTICE ADVICE 13: Administration of vitamin E may be considered in lean persons with biopsy-confirmed nonalcoholic steatohepatitis, but without type 2 diabetes mellitus or cirrhosis. Oral pioglitazone 30 mg daily may be considered in lean persons with biopsy-confirmed nonalcoholic steatohepatitis without cirrhosis. BEST PRACTICE ADVICE 14: The therapeutic role of glucagon-like peptide-1 agonists and sodium-glucose cotransporter-2 inhibitors in the management of lean NAFLD is not fully defined and requires further investigation. BEST PRACTICE ADVICE 15: Hepatocellular carcinoma surveillance with abdominal ultrasound with or without serum α-fetoprotein twice per year is suggested in patients with lean NAFLD and clinical markers compatible with liver cirrhosis.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Long MT, Noureddin M, Lim JK, et al. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology. 2022. PMID: 35842345. doi:10.1053/j.gastro.2022.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。